Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06417710 · ClinicalTrials.gov registry record
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
A clinical trial of Leptomeningeal Metastasis and Leptomeningeal Disease, sponsored by University of Zurich.
- Recruiting
- Registry status
- 200
- Enrollment target
- 3
- Study locations
NCT06417710 is a study of Leptomeningeal Metastasis and Leptomeningeal Disease that is actively recruiting participants, run by University of Zurich. The registered enrollment target is 200 participants, above the 27-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (641% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT06417710, a study of Leptomeningeal Metastasis and Leptomeningeal Disease, is actively recruiting participants, sponsored by University of Zurich.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.
Conditions Studied
Interventions
- OTHER Neurological Assessment
Study Locations (3)
Other
- Netherlands Cancer Institute - Amsterdam
- University Hospital Zurich - Zurich
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-01-30 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06417710
The ClinicalTrials.gov registry entry for NCT06417710 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 27-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (641% higher). The listed sponsor is University of Zurich, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Leptomeningeal Metastasis appearing as the primary indexed condition, and to 1 intervention - of which Neurological Assessment is the first listed.
NCT06417710 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.
Frequently Asked Questions
What is clinical trial NCT06417710 about?
NCT06417710 is a clinical study titled "Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis". The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.
What is the current status of trial NCT06417710?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-01-30. Estimated completion is 2026-12.
What conditions does trial NCT06417710 study?
This clinical trial studies the following conditions: Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Leptomeningeal Cancer.
What interventions are being tested in trial NCT06417710?
The interventions under investigation include: Neurological Assessment (OTHER).
Who is sponsoring clinical trial NCT06417710?
This trial is sponsored by University of Zurich, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06417710 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leptomeningeal Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
RECRUITING · Phase 1
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
-
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.